Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical (Nasdaq: OM), a medical technology company focused on reducing the cost and complexity of dialysis, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. The presentation is scheduled for June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast will be accessible via the 'Investors' section of the Outset Medical website.
Outset Medical, Inc. reported its financial results for the first quarter of 2024, highlighting revenue of $28.2 million, a 12% growth in service and other revenue, and a total gross margin improvement to 29.2%. Operating expenses decreased by 10% from the prior year. The company remains focused on reducing costs, achieving profitability, and capitalizing on the $11 billion U.S. dialysis market opportunity.
Outset Medical, Inc. (Nasdaq: OM) received FDA 510(k) clearance for TabloCart with prefiltration, an accessory for the Tablo Hemodialysis System, improving flexibility for healthcare providers. This innovative technology enhances user experience with versatile prefiltration options and enhanced maneuverability, simplifying dialysis treatment. TabloCart complements Tablo as a single enterprise solution, revolutionizing the dialysis experience for patients and providers.
Outset Medical, a medical technology company (OM), will be presenting at upcoming investor conferences hosted by BofA Securities and RBC Capital Markets in May 2024. The management will discuss the company's innovative dialysis technology to reduce costs and complexity. Webcasts of the sessions will be available on Outset's investor section website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.